Watson I D, Cohen H N, McIntosh S J, Thomson J A, Shenkin A
Clin Ther. 1981;4(2):103-8.
In a randomized, crossover, multiple dose study, ten healthy volunteers received the recommended dosages of cotrimoxazole (80 mg trimethoprim and 400 mg sulfamethoxazole) and co-tri-famole (80 mg trimethoprim and 400 mg sulfamoxole) for five days each. Urinary levels of trimethoprim and each sulfonamide were measured daily for five days. The urinary ratios of trimethoprim and sulfonamide for both formulations were consistently lower than those considered optimal for synergy. Concentration of trimethoprim in the urine from both preparations was found to be greatly in excess of the MIC for trimethoprim-sensitive urinary pathogens (approximately 2 microgram/ml). The sulfonamide levels achieved were not consistently in excess of their MIC (approximately 200 microgram/ml) for either preparation.
在一项随机、交叉、多剂量研究中,10名健康志愿者分别接受了推荐剂量的复方新诺明(80毫克甲氧苄啶和400毫克磺胺甲恶唑)和复方磺胺异恶唑(80毫克甲氧苄啶和400毫克磺胺异恶唑),各服用5天。连续5天每天测量甲氧苄啶和每种磺胺类药物的尿药浓度。两种制剂的甲氧苄啶与磺胺类药物的尿药比值始终低于认为具有协同作用的最佳比值。发现两种制剂尿液中的甲氧苄啶浓度大大超过对甲氧苄啶敏感的尿路病原体的最低抑菌浓度(约2微克/毫升)。两种制剂所达到的磺胺类药物水平并非始终超过其最低抑菌浓度(约200微克/毫升)。